Core - Pharmacology Core Laboratory

Connor, James D.

Abstract

The broad objective of the PHARMACOLOGY CORE LABORATORY is to enhance AIDS treatment programs through provision of essential and substantive pharmacologic data on antiretroviral drugs, and as well, other drugs, or substances which may be used beneficially, in the treatment of AIDS Complex Diseases.
The specific aims of the PHARMACOLOGY CORE LABORATORY are: 1. to continue to develop, standardize, and to adapt accurate, dependable and expedient assays for use in pharmacology and pharmacokinetics of experimental and approved drugs which may prove therapeutic for HIV infections and in AIDS; 2. to continue to offer these assays through the means of a service oriented assay laboratory in support of new and ongoing studies of AIDS treatment; 3. to continue to provide essential pharmacokinetic and pharmacologic data on experimental and approved drugs, as a means of bringing effective drugs into clinical use as rapidly as possible. This project is an integral part of the U.S. Program on AIDS treatment, conducted through the Division of AIDS (DAIDS), NIAID, NIH, Dept. of HHS.

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Institute of Allergy and Infectious Diseases (NIAID)
• Type: Research Project--Cooperative Agreements (U01)
• Project #: 5U01AI027670-09
• Application #: 3727190
• Support Year: 9
• Fiscal Year: 1995

Institution

• Name: University of California San Diego
• DUNS #: 077758407
• City: La Jolla
• State: CA
• Country: United States
• Zip Code: 92093

Publications

Beliakova-Bethell, Nadejda; Hezareh, Marjan; Wong, Joseph K et al. (2017) Relative efficacy of T cell stimuli as inducers of productive HIV-1 replication in latently infected CD4 lymphocytes from patients on suppressive cART. Virology 508:127-133

Osorio, Georgina; Hoenigl, Martin; Quartarolo, Jennifer et al. (2017) Evaluation of opt-out inpatient HIV screening at an urban teaching hospital. AIDS Care 29:1014-1018

Dan, Jennifer M; Massanella, Marta; Smith, Davey M et al. (2016) Brief Report: Effect of CMV and HIV Transcription on CD57 and PD-1 T-Cell Expression During Suppressive ART. J Acquir Immune Defic Syndr 72:133-7

Innes, Steve; Abdullah, Kameelah L; Haubrich, Richard et al. (2016) High Prevalence of Dyslipidemia and Insulin Resistance in HIV-infected Prepubertal African Children on Antiretroviral Therapy. Pediatr Infect Dis J 35:e1-7

Vanpouille, Christophe; Introini, Andrea; Morris, Sheldon R et al. (2016) Distinct cytokine/chemokine network in semen and blood characterize different stages of HIV infection. AIDS 30:193-201

Gianella, Sara; Ginocchio, Christine C; Daar, Eric S et al. (2016) Genital Epstein Barr Virus is associated with higher prevalence and persistence of anal human papillomavirus in HIV-infected men on antiretroviral therapy. BMC Infect Dis 16:24

Blumenthal, Jill; Jain, Sonia; Krakower, Douglas et al. (2015) Knowledge is Power! Increased Provider Knowledge Scores Regarding Pre-exposure Prophylaxis (PrEP) are Associated with Higher Rates of PrEP Prescription and Future Intent to Prescribe PrEP. AIDS Behav 19:802-10

Krishnan, Supriya; Schouten, Jeffrey T; Atkinson, Benjamin et al. (2015) Changes in metabolic syndrome status after initiation of antiretroviral therapy. J Acquir Immune Defic Syndr 68:73-80

Massanella, Marta; Gianella, Sara; Schrier, Rachel et al. (2015) Methamphetamine Use in HIV-infected Individuals Affects T-cell Function and Viral Outcome during Suppressive Antiretroviral Therapy. Sci Rep 5:13179

Gianella, Sara; Smith, Davey M; Daar, Eric S et al. (2015) Genital Cytomegalovirus Replication Predicts Syphilis Acquisition among HIV-1 Infected Men Who Have Sex with Men. PLoS One 10:e0130410